Trial Outcomes & Findings for A Study of LY3437943 in Participants With Type 2 Diabetes (NCT NCT04867785)

Last Updated: 2023-07-03

Results Overview

Change in HbA1c (%) from baseline in LY3437943 relative to placebo. HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

281 participants

Primary outcome timeframe

Baseline, 24 Weeks

Results posted on

2023-07-03

Participant Flow

Four maintenance doses of LY3437943 were evaluated: 0.5 mg, 4 mg, 8 mg, and 12 mg. Dose escalation occurred in certain cohorts up to Week 12 during the 36-week treatment period. For maintenance doses equal to or greater than 4 mg, the initial dose will be 2 mg or 4 mg followed by additional escalation steps as appropriate.

Participant milestones

Participant milestones
Measure	Placebo Participants received placebo administered as subcutaneous (SC) injection once weekly (QW).	1.5 Milligrams (mg) Dulaglutide Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as a SC injection QW.	12 mg LY3437943 (2 mg) Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.
Overall Study STARTED	45	46	47	23	24	26	24	46
Overall Study Received at Least 1 Dose of Study Drug	45	46	47	23	24	26	24	46
Overall Study COMPLETED	34	40	41	19	21	25	22	35
Overall Study NOT COMPLETED	11	6	6	4	3	1	2	11

Reasons for withdrawal

Reasons for withdrawal
Measure	Placebo Participants received placebo administered as subcutaneous (SC) injection once weekly (QW).	1.5 Milligrams (mg) Dulaglutide Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as a SC injection QW.	12 mg LY3437943 (2 mg) Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.
Overall Study Adverse Event	1	0	1	0	0	0	0	2
Overall Study Lost to Follow-up	4	4	3	2	0	1	0	1
Overall Study Withdrawal by Subject	6	2	2	1	2	0	2	5
Overall Study Physician Decision	0	0	0	0	0	0	0	1
Overall Study Inadvertent Enrollment	0	0	0	1	1	0	0	1
Overall Study Eligibility Criteria Not Met	0	0	0	0	0	0	0	1

Baseline Characteristics

A Study of LY3437943 in Participants With Type 2 Diabetes

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo n=45 Participants Participants received placebo administered as SC injection QW.	1.5 mg Dulaglutide n=46 Participants Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 n=47 Participants Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) n=23 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) n=26 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.	12 mg LY3437943 (2 mg) n=46 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.	Total n=281 Participants Total of all reporting groups
Age, Continuous	57.56 years STANDARD_DEVIATION 10.83 • n=5 Participants	54.94 years STANDARD_DEVIATION 10.45 • n=7 Participants	57.21 years STANDARD_DEVIATION 9.69 • n=5 Participants	57.70 years STANDARD_DEVIATION 8.14 • n=4 Participants	57.58 years STANDARD_DEVIATION 10.00 • n=21 Participants	57.00 years STANDARD_DEVIATION 7.37 • n=8 Participants	53.83 years STANDARD_DEVIATION 9.03 • n=8 Participants	54.37 years STANDARD_DEVIATION 9.72 • n=24 Participants	56.19 years STANDARD_DEVIATION 9.68 • n=42 Participants
Sex: Female, Male Female	23 Participants n=5 Participants	33 Participants n=7 Participants	23 Participants n=5 Participants	8 Participants n=4 Participants	12 Participants n=21 Participants	16 Participants n=8 Participants	15 Participants n=8 Participants	26 Participants n=24 Participants	156 Participants n=42 Participants
Sex: Female, Male Male	22 Participants n=5 Participants	13 Participants n=7 Participants	24 Participants n=5 Participants	15 Participants n=4 Participants	12 Participants n=21 Participants	10 Participants n=8 Participants	9 Participants n=8 Participants	20 Participants n=24 Participants	125 Participants n=42 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	21 Participants n=5 Participants	20 Participants n=7 Participants	27 Participants n=5 Participants	9 Participants n=4 Participants	13 Participants n=21 Participants	12 Participants n=8 Participants	9 Participants n=8 Participants	20 Participants n=24 Participants	131 Participants n=42 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	23 Participants n=5 Participants	26 Participants n=7 Participants	20 Participants n=5 Participants	14 Participants n=4 Participants	10 Participants n=21 Participants	14 Participants n=8 Participants	15 Participants n=8 Participants	26 Participants n=24 Participants	148 Participants n=42 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	2 Participants n=42 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	2 Participants n=24 Participants	2 Participants n=42 Participants
Race (NIH/OMB) Asian	3 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	2 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	2 Participants n=24 Participants	8 Participants n=42 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Black or African American	5 Participants n=5 Participants	9 Participants n=7 Participants	6 Participants n=5 Participants	1 Participants n=4 Participants	2 Participants n=21 Participants	3 Participants n=8 Participants	4 Participants n=8 Participants	3 Participants n=24 Participants	33 Participants n=42 Participants
Race (NIH/OMB) White	36 Participants n=5 Participants	36 Participants n=7 Participants	40 Participants n=5 Participants	20 Participants n=4 Participants	22 Participants n=21 Participants	23 Participants n=8 Participants	20 Participants n=8 Participants	38 Participants n=24 Participants	235 Participants n=42 Participants
Race (NIH/OMB) More than one race	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	2 Participants n=42 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	1 Participants n=24 Participants	1 Participants n=42 Participants
Region of Enrollment United States	45 participants n=5 Participants	46 participants n=7 Participants	47 participants n=5 Participants	23 participants n=4 Participants	24 participants n=21 Participants	26 participants n=8 Participants	24 participants n=8 Participants	46 participants n=24 Participants	281 participants n=42 Participants
Percentage of Hemoglobin A1c (HbA1c) at Baseline	8.39 Percentage of HbA1c STANDARD_DEVIATION 1.139 • n=5 Participants	8.22 Percentage of HbA1c STANDARD_DEVIATION 0.919 • n=7 Participants	8.35 Percentage of HbA1c STANDARD_DEVIATION 1.172 • n=5 Participants	8.07 Percentage of HbA1c STANDARD_DEVIATION 0.870 • n=4 Participants	8.20 Percentage of HbA1c STANDARD_DEVIATION 1.207 • n=21 Participants	8.34 Percentage of HbA1c STANDARD_DEVIATION 1.120 • n=8 Participants	8.20 Percentage of HbA1c STANDARD_DEVIATION 1.261 • n=8 Participants	8.28 Percentage of HbA1c STANDARD_DEVIATION 1.066 • n=24 Participants	8.27 Percentage of HbA1c STANDARD_DEVIATION 1.086 • n=42 Participants

PRIMARY outcome

Timeframe: Baseline, 24 Weeks

Population: All randomized participants with baseline and post-baseline value at the specified time point excluding participants discontinuing study drug due to inadvertent enrollment and data after permanent discontinuation of study drug or initiation of rescue medication.

Outcome measures

Outcome measures
Measure	Placebo n=45 Participants Participants received placebo administered as SC injection QW.	1.5 mg Dulaglutide n=46 Participants Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 n=46 Participants Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) n=22 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) n=25 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.	12 mg LY3437943 (2 mg) n=43 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.
Change From Baseline in Hemoglobin A1c (HbA1c)	-0.05 percentage of HbA1c Standard Error 0.21	-1.41 percentage of HbA1c Standard Error 0.12	-0.43 percentage of HbA1c Standard Error 0.20	-1.39 percentage of HbA1c Standard Error 0.14	-1.30 percentage of HbA1c Standard Error 0.22	-1.99 percentage of HbA1c Standard Error 0.15	-1.88 percentage of HbA1c Standard Error 0.21	-2.01 percentage of HbA1c Standard Error 0.11

SECONDARY outcome

Timeframe: Baseline, 24 Weeks

Change in HbA1c (%) from baseline in LY3437943 relative to dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.

Outcome measures

Outcome measures
Measure	Placebo n=45 Participants Participants received placebo administered as SC injection QW.	1.5 mg Dulaglutide n=46 Participants Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 n=46 Participants Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) n=22 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) n=25 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.	12 mg LY3437943 (2 mg) n=43 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.
Change From Baseline in HbA1c	-0.05 percentage of HbA1c Standard Error 0.21	-1.41 percentage of HbA1c Standard Error 0.12	-0.43 percentage of HbA1c Standard Error 0.20	-1.39 percentage of HbA1c Standard Error 0.14	-1.30 percentage of HbA1c Standard Error 0.22	-1.99 percentage of HbA1c Standard Error 0.15	-1.88 percentage of HbA1c Standard Error 0.21	-2.01 percentage of HbA1c Standard Error 0.11

SECONDARY outcome

Timeframe: Baseline, 36 Weeks

Change in HbA1c (%) from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Baseline HbA1c Group (\<=8.5%, \>8.5%)\*Time + Baseline Body Mass Index (BMI) Group (\<30 kilograms/square meter (kg/m2), \>=30 kg/m2)\*Time + Baseline\*Time.

Outcome measures

Outcome measures
Measure	Placebo n=45 Participants Participants received placebo administered as SC injection QW.	1.5 mg Dulaglutide n=46 Participants Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 n=46 Participants Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) n=22 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) n=25 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.	12 mg LY3437943 (2 mg) n=43 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.
Change From Baseline in HbA1c	-0.30 percentage of HbA1c Standard Error 0.24	-1.36 percentage of HbA1c Standard Error 0.13	-0.54 percentage of HbA1c Standard Error 0.20	-1.30 percentage of HbA1c Standard Error 0.20	-1.50 percentage of HbA1c Standard Error 0.19	-2.13 percentage of HbA1c Standard Error 0.17	-1.93 percentage of HbA1c Standard Error 0.22	-2.16 percentage of HbA1c Standard Error 0.13

SECONDARY outcome

Timeframe: Week 24

Percentage of participants reaching HbA1c \<7.0% in LY3437943 relative to placebo and dulaglutide. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<30 kg/m2, ≥30 kg/m2\] as fixed effects, and baseline HbA1c value as a covariate.

Outcome measures

Outcome measures
Measure	Placebo n=45 Participants Participants received placebo administered as SC injection QW.	1.5 mg Dulaglutide n=46 Participants Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 n=46 Participants Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) n=22 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) n=25 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.	12 mg LY3437943 (2 mg) n=43 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.
Percentage of Participants Reaching HbA1c <7.0%	18 percentage of participants	52 percentage of participants	32 percentage of participants	53 percentage of participants	66 percentage of participants	88 percentage of participants	78 percentage of participants	86 percentage of participants

SECONDARY outcome

Timeframe: Week 36

Outcome measures

Outcome measures
Measure	Placebo n=45 Participants Participants received placebo administered as SC injection QW.	1.5 mg Dulaglutide n=46 Participants Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 n=46 Participants Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) n=22 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) n=25 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.	12 mg LY3437943 (2 mg) n=43 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.
Percentage of Participant Reaching HbA1c <7.0%	22 percentage of participants	60 percentage of participants	37 percentage of participants	61 percentage of participants	59 percentage of participants	82 percentage of participants	78 percentage of participants	80 percentage of participants

SECONDARY outcome

Timeframe: Baseline, 24 Weeks

Change in FBG from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.

Outcome measures

Outcome measures
Measure	Placebo n=45 Participants Participants received placebo administered as SC injection QW.	1.5 mg Dulaglutide n=46 Participants Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 n=46 Participants Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) n=22 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) n=25 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.	12 mg LY3437943 (2 mg) n=43 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.
Change From Baseline in Fasting Blood Glucose (FBG)	-10.59 milligrams/deciliter (mg/dL) Standard Error 5.98	-46.26 milligrams/deciliter (mg/dL) Standard Error 4.35	-12.71 milligrams/deciliter (mg/dL) Standard Error 6.95	-30.19 milligrams/deciliter (mg/dL) Standard Error 12.65	-43.89 milligrams/deciliter (mg/dL) Standard Error 8.42	-66.09 milligrams/deciliter (mg/dL) Standard Error 3.70	-39.80 milligrams/deciliter (mg/dL) Standard Error 10.79	-65.20 milligrams/deciliter (mg/dL) Standard Error 4.38

SECONDARY outcome

Timeframe: Baseline, 36 Weeks

Change in FBG from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Baseline HbA1c Group (\<=8.5%, \>8.5%)\*Time + Baseline BMI Group (\<30kg/m2, \>=30kg/m2)\*Time + Baseline\*Time.

Outcome measures

Outcome measures
Measure	Placebo n=45 Participants Participants received placebo administered as SC injection QW.	1.5 mg Dulaglutide n=46 Participants Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 n=46 Participants Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) n=22 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) n=25 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.	12 mg LY3437943 (2 mg) n=43 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.
Change From Baseline in Fasting Blood Glucose (FBG)	-17.26 mg/dL Standard Error 10.87	-27.53 mg/dL Standard Error 9.07	-17.51 mg/dL Standard Error 5.59	-21.46 mg/dL Standard Error 12.54	-38.72 mg/dL Standard Error 10.81	-69.10 mg/dL Standard Error 4.68	-41.20 mg/dL Standard Error 14.43	-67.84 mg/dL Standard Error 4.79

SECONDARY outcome

Timeframe: Baseline, 24 Weeks

Change in body weight from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.

Outcome measures

Outcome measures
Measure	Placebo n=45 Participants Participants received placebo administered as SC injection QW.	1.5 mg Dulaglutide n=46 Participants Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 n=46 Participants Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) n=22 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) n=25 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.	12 mg LY3437943 (2 mg) n=43 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.
Change From Baseline in Body Weight	-1.86 kilograms (kg) Standard Error 0.66	-1.16 kilograms (kg) Standard Error 0.63	-2.35 kilograms (kg) Standard Error 0.48	-6.27 kilograms (kg) Standard Error 0.94	-8.64 kilograms (kg) Standard Error 1.23	-11.99 kilograms (kg) Standard Error 0.84	-13.91 kilograms (kg) Standard Error 1.38	-12.84 kilograms (kg) Standard Error 0.93

SECONDARY outcome

Timeframe: Baseline, 36 Weeks

Outcome measures

Outcome measures
Measure	Placebo n=45 Participants Participants received placebo administered as SC injection QW.	1.5 mg Dulaglutide n=46 Participants Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 n=46 Participants Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) n=22 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) n=25 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.	12 mg LY3437943 (2 mg) n=43 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.
Change From Baseline in Body Weight	-3.28 kilograms (kg) Standard Error 0.92	-1.97 kilograms (kg) Standard Error 0.87	-3.31 kilograms (kg) Standard Error 0.62	-7.28 kilograms (kg) Standard Error 1.39	-10.37 kilograms (kg) Standard Error 1.49	-16.48 kilograms (kg) Standard Error 1.55	-16.12 kilograms (kg) Standard Error 1.63	-17.18 kilograms (kg) Standard Error 1.32

SECONDARY outcome

Timeframe: Predose: Week 0, 1, 4, 12, 24, 30; Postdose: Week 2, 8, 16, 20, 36

Population: All randomized participants who received at least one dose of study drug and had evaluable PK data.

The average steady-state plasma concentration of LY3437943 was evaluated using sparse sampling methodology/Population PK (PopPK) modeling.

Outcome measures

Outcome measures
Measure	Placebo n=46 Participants Participants received placebo administered as SC injection QW.	1.5 mg Dulaglutide n=21 Participants Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 n=24 Participants Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) n=26 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) n=24 Participants Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) n=46 Participants Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.	12 mg LY3437943 (2 mg) Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.
Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943	62.8 nanograms/milliliter (ng/mL)	466 nanograms/milliliter (ng/mL)	551 nanograms/milliliter (ng/mL)	1100 nanograms/milliliter (ng/mL)	1140 nanograms/milliliter (ng/mL)	1620 nanograms/milliliter (ng/mL)	—	—

Adverse Events

Placebo

Serious events: 3 serious events

Other events: 15 other events

Deaths: 0 deaths

1.5 Milligram (mg) Dulaglutide

Serious events: 1 serious events

Other events: 24 other events

Deaths: 0 deaths

0.5 mg LY3437943

Serious events: 3 serious events

Other events: 15 other events

Deaths: 0 deaths

4 mg LY3437943 (2 mg)

Serious events: 1 serious events

Other events: 9 other events

Deaths: 0 deaths

4 mg LY3437943 (4 mg)

Serious events: 2 serious events

Other events: 17 other events

Deaths: 0 deaths

8 mg LY3437943 (2 mg)

Serious events: 2 serious events

Other events: 16 other events

Deaths: 0 deaths

8 mg LY3437943 (4 mg)

Serious events: 1 serious events

Other events: 15 other events

Deaths: 0 deaths

12 mg LY3437943 (2 mg)

Serious events: 2 serious events

Other events: 25 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Placebo n=45 participants at risk Participants received placebo administered as SC injection QW.	1.5 Milligram (mg) Dulaglutide n=46 participants at risk Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 n=47 participants at risk Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) n=23 participants at risk Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) n=24 participants at risk Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) n=26 participants at risk Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) n=24 participants at risk Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.	12 mg LY3437943 (2 mg) n=46 participants at risk Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.
Cardiac disorders Atrial fibrillation	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	3.8% 1/26 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Cardiac disorders Cardiac failure congestive	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.1% 1/47 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 1/23 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Abdominal hernia	2.2% 1/45 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Pancreatitis acute	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.1% 1/47 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	3.8% 1/26 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Hepatobiliary disorders Cholecystitis chronic	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Cellulitis	2.2% 1/45 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.2% 1/46 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Osteomyelitis acute	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Injury, poisoning and procedural complications Fibula fracture	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.1% 1/47 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Metabolism and nutrition disorders Diabetic ketoacidosis	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.2% 1/46 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Lumbar spinal stenosis	2.2% 1/45 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Spinal osteoarthritis	2.2% 1/45 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Renal and urinary disorders Acute kidney injury	2.2% 1/45 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.1% 1/47 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Surgical and medical procedures Spinal fusion surgery	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.2% 1/46 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Surgical and medical procedures Transurethral prostatectomy	4.5% 1/22 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/13 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/15 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/12 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/10 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/9 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/20 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

Other adverse events

Other adverse events
Measure	Placebo n=45 participants at risk Participants received placebo administered as SC injection QW.	1.5 Milligram (mg) Dulaglutide n=46 participants at risk Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.	0.5 mg LY3437943 n=47 participants at risk Participants received 0.5 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (2 mg) n=23 participants at risk Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.	4 mg LY3437943 (4 mg) n=24 participants at risk Participants received 4 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (2 mg) n=26 participants at risk Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.	8 mg LY3437943 (4 mg) n=24 participants at risk Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.	12 mg LY3437943 (2 mg) n=46 participants at risk Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as SC injection QW.
Blood and lymphatic system disorders Anaemia	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.3% 2/24 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 2/46 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Abdominal pain	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 1/23 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	3.8% 1/26 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.3% 2/24 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.2% 1/46 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Constipation	2.2% 1/45 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	6.5% 3/46 • Number of events 4 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	6.4% 3/47 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.7% 2/23 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 4/24 • Number of events 5 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.5% 3/26 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.3% 2/24 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	10.9% 5/46 • Number of events 6 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Diarrhoea	4.4% 2/45 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.7% 4/46 • Number of events 5 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.1% 1/47 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.7% 2/23 • Number of events 5 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 6/24 • Number of events 7 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	19.2% 5/26 • Number of events 10 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	29.2% 7/24 • Number of events 9 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	15.2% 7/46 • Number of events 8 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Dyspepsia	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 2/46 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.1% 1/47 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	7.7% 2/26 • Number of events 4 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	6.5% 3/46 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Eructation	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 2/46 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.1% 1/47 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	3.8% 1/26 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.3% 2/24 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.2% 1/46 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Flatulence	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.2% 1/46 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	12.5% 3/24 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Nausea	4.4% 2/45 • Number of events 4 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	17.4% 8/46 • Number of events 13 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 2/47 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.7% 2/23 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 6/24 • Number of events 9 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	26.9% 7/26 • Number of events 9 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	41.7% 10/24 • Number of events 15 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	19.6% 9/46 • Number of events 13 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Vomiting	2.2% 1/45 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.7% 4/46 • Number of events 5 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.1% 1/47 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 1/23 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	7.7% 2/26 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 4/24 • Number of events 5 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	10.9% 5/46 • Number of events 11 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Fatigue	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.1% 1/47 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 1/23 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.3% 2/24 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	3.8% 1/26 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	12.5% 3/24 • Number of events 4 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	6.5% 3/46 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Covid-19	6.7% 3/45 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.7% 4/46 • Number of events 4 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	10.6% 5/47 • Number of events 5 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	13.0% 3/23 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	3.8% 1/26 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 2/46 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Nasopharyngitis	2.2% 1/45 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	6.5% 3/46 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Sinusitis	4.4% 2/45 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.2% 1/46 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	7.7% 2/26 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Upper respiratory tract infection	4.4% 2/45 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.2% 1/46 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	3.8% 1/26 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.3% 2/24 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	10.9% 5/46 • Number of events 5 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Urinary tract infection	4.4% 2/45 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.2% 1/46 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	3.8% 1/26 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	12.5% 3/24 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	10.9% 5/46 • Number of events 6 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Vaginal infection	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/33 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/8 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/12 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/16 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	6.7% 1/15 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Lipase increased	4.4% 2/45 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.2% 1/46 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.1% 1/47 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 1/23 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.3% 2/24 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.5% 3/26 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 2/46 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Weight decreased	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 1/23 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	7.7% 2/26 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 2/46 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	13.0% 6/46 • Number of events 6 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 2/47 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 1/23 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	20.8% 5/24 • Number of events 5 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	19.2% 5/26 • Number of events 5 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 4/24 • Number of events 4 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	19.6% 9/46 • Number of events 9 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Nervous system disorders Dizziness	2.2% 1/45 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.2% 1/46 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/47 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.7% 2/23 • Number of events 4 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.3% 2/24 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	3.8% 1/26 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	12.5% 3/24 • Number of events 4 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 2/46 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Nervous system disorders Headache	4.4% 2/45 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	6.5% 3/46 • Number of events 3 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 2/47 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.3% 1/23 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.5% 3/26 • Number of events 4 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	4.2% 1/24 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.2% 1/46 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Reproductive system and breast disorders Penile swelling	0.00% 0/22 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	7.7% 1/13 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/15 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/12 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/10 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/9 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/20 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Reproductive system and breast disorders Vaginal haemorrhage	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/33 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/23 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/8 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/12 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	6.2% 1/16 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/15 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/45 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.2% 1/46 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	2.1% 1/47 • Number of events 1 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	8.7% 2/23 • Number of events 2 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/26 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/24 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/46 • Baseline Through Study Completion (Up to 280 Days) All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

Additional Information

Chief Medical Officer

Eli Lilly and Company

Phone: 800-545-5979

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: GT60